MedPath

Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

Terminated
Conditions
Biomarker With Neurodegeneration Patients
Registration Number
NCT01564316
Lead Sponsor
Seoul National University Hospital
Brief Summary

Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Detailed Description

Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • neurodegeneration patients and control group include dementia patients visited the part of neurology.
  • over the age of 18
  • when participants can understand subject of this study
  • Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points.

exclusion criteria:

  • under eighteen years of age
  • when participants cannot understand subject of this study
  • cannot accept this study
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Neurology, Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath